Effect of Inflammation and Benign Prostatic Hyperplasia on Elevated Serum Prostate Specific Antigen Levels

Nadler, Robert B.; Humphrey, Peter A.; Smith, Deborah S.; Catàlona, William J.; Ratliff, Timothy L.

doi:10.1097/00005392-199508000-00023

Cited by 257 publications

(217 citation statements)

References 17 publications

Supporting

Mentioning

198

Contrasting

Unclassified

Order By: Relevance

“…It recommended in USA and Europe that the positive serum tPSA candidates, whose serum tPSA value is 44.0 ng/ml, should be subject to transrectal ultrasoundguided prostate needle-biopsy. 3 What is the performance of PSA for prostate cancer in Chinese, the lower incidence country? A systematic review and metaanalysis were performed to determine the diagnostic ability of PSA tests for prostate cancer in Chinese.…”

Section: Introductionmentioning

confidence: 99%

Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis

Wang

Sun

Pan

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Performing a systematic review and meta-analysis to evaluate the diagnostic performance of the total prostate-specific antigen (tPSA) tests for diagnosis of prostate cancer among Chinese. Literatures related to diagnosis of prostate cancer by tPSA and the ratio of free to total PSA (f/tPSA) being retrieved in five electronic databases. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio (DOR) were pooled using random effects models. Summary receiver operating characteristic curves (SROC) used to summarize overall test performance. In total 10 studies meting the inclusion criteria, 2256 patients were included. Among them 423 were patients of prostate cancer compared to 1833 were patients of benign prostate hyperplasia (BPH). The pooled sensitivity and specificity of tPSA44.0 ng/ml, tPSA410.0 ng/ml and f/tPSAo0.15 as threshold for the diagnosis of prostate cancer were heterogeneity. The areas under SROC (AUC) were 80, 85 and 87%, respectively (Po0.05). The pooled DOR were 8.44(95%CI: 4.45B16.00), 9.94(95%CI: 4.15B23.77) and 13.75(95%CI: 6.35B29.76), respectively (Po0.05). v 2 test used for testing the heterogeneity. tPSA and f/tPSA made an important performance for diagnosis of prostate cancer in decade among Chinese. The use of f/tPSAo0.15 as threshold maintain a high prognostic accuracy for prostate cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis

Wang

Sun

Pan

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Serum PSA levels may be increased in BPH [11,12], prostatitis [12], prostate cancer [13], and following prostate biopsy/massage [14], DRE [15,16], colonoscopy [17], and cystoscopy [18]. Serum PSA has been traditionally used as a diagnostic tool in conjunction with DRE for the early diagnosis and management of prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Does Rigid Cystoscopy Affect the Total Serum Prostate-Specific Antigen Levels?

2013

View full text Add to dashboard Cite

show abstract

“…Several conditions can produce a rise in serum PSA levels. These include benign enlargement, inflammation, and the presence of prostate cancer [18]. When first described in 1979, PSA was promoted as a useful marker for assessing treatment responses among patients with prostate cancer [19].…”

Section: Screening For Prostate Cancer With Psa (The Test)mentioning

confidence: 99%

Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?

Albertsen

2005

Acta Oncologica

View full text Add to dashboard Cite

Screening and treatment for prostate cancer is controversial. In the absence of randomized trials, several prominent medical organizations in the United States and Europe have formulated policies that range from enthusiastic support to significant skepticism concerning the efficacy of screening and subsequent treatment for prostate cancer. Sharp rises in the incidence of prostate cancer have occurred whenever PSA testing has been introduced on a wide scale. Unfortunately, it is unclear whether declines in prostate cancer mortality can be attributed to PSA testing. Other explanations include the early use of anti-androgen therapy or changes in environmental factors such as diet. Repeated testing for serum PSA has produced significant shifts in the types of cases being identified and has raised the possibility of significant over-diagnosis of this disease. The European screening trial and the PLCO trial in the US will hopefully provide some insights into the value of population-based testing.

show abstract

Effect of Inflammation and Benign Prostatic Hyperplasia on Elevated Serum Prostate Specific Antigen Levels

Abstract: Prostate volume and inflammation are the most important factors contributing to serum PSA elevation in men without clinically detectable prostate cancer.

Cited by 257 publications

References 17 publications

Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis

Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis

Does Rigid Cystoscopy Affect the Total Serum Prostate-Specific Antigen Levels?

Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?

Contact Info

Product

Resources

About